Vertex Pharmaceuticals Incorporated (VRTX)
| Previous Close | 397.70 |
| Open | 393.52 |
| Bid | 397.21 x 100 |
| Ask | 398.15 x 100 |
| Day's Range | 393.49 - 397.81 |
| 52 Week Range | 320.01 - 448.40 |
| Volume | |
| Avg. Volume | 1,202,646 |
| Market Cap | 102.789B |
| Beta (5Y Monthly) | 0.37 |
| PE Ratio (TTM) | 28.65 |
| EPS (TTM) | 13.88 |
| Earnings Date | May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 465.42 |
ZacksThe Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksVertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.
- Reuters
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday. Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular "scissors" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA.
